DHR
A lighter haircut, not a breakup
TD Cowen just took a pair of scissors to Danaher’s price target, cutting it to $245 from $270, while keeping the stock on Buy. In other words: the analyst crowd is still in Danaher’s corner, but they’re not exactly racing to the rooftop with confetti.
The message behind the math
Price-target cuts usually say more about expectations than panic. If you’re an investor, the key takeaway is that TD Cowen still thinks Danaher can climb from here — just not quite as far as it thought a few weeks ago. That matters because Danaher has already been living in the “show me” zone, with shares down 15.67% for the year even after a recent bounce.
Not a solo act
TD Cowen wasn’t out there making this call in a vacuum either. Goldman Sachs also trimmed its target on Danaher, to $230 from $265, while keeping a Buy rating. So the vibe is basically: “We still like the company, but the road just got a little bumpier.”
Big picture
For Danaher holders, this isn’t the kind of note that blows up the thesis. But it is a reminder that even blue-chip-ish life sciences names don’t get a free pass when analysts start recalibrating their models. The stock can still work — just maybe with fewer fireworks and a little more patience.